Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates. [More]
Coordinated, two-part approach could help reduce hospital-acquired infections

Coordinated, two-part approach could help reduce hospital-acquired infections

By coordinating with state health departments and communicating with each other about patients with C. difficile and antibiotic-resistant infections, hospitals, long-term acute-care facilities and nursing homes could reduce the number of such hospital-acquired infections (HAIs) by an estimated 619,000 cases in the next five years, a new Centers for Disease Control 9 (CDC)-led report has found. [More]
UBC scientists reveal new weapon to combat malnutrition

UBC scientists reveal new weapon to combat malnutrition

UBC scientists have opened the doors to new research into malnutrition by creating an animal model that replicates the imbalance of gut bacteria associated with the difficult-to-treat disease. [More]

Par Pharmaceutical starts shipment of generic version of Sodium Edecrin

Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg. [More]
BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks. [More]
Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections. [More]
Hand washing tips to protect against many infections

Hand washing tips to protect against many infections

As the beginning of the school year approaches, parents need to remind their children about the importance of hand washing. Every day people touch several surfaces including books, desks, door knobs, sink handles, and other people and many of them harbor germs like bacteria and viruses that can cause illnesses. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Georgia researchers develop new tools to genetically manipulate parasite that causes cryptosporidiosis

Georgia researchers develop new tools to genetically manipulate parasite that causes cryptosporidiosis

Researchers at the University of Georgia have developed new tools to study and genetically manipulate cryptosporidium, a microscopic parasite that causes the diarrheal disease cryptosporidiosis. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. [More]
UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections. [More]
Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca. [More]
Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative colitis (UC). [More]
Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel. [More]
Study provides insights into the cause of irritable bowel syndrome

Study provides insights into the cause of irritable bowel syndrome

A team comprised of scientists at VIB, KU Leuven and UZ Leuven has made significant progress in uncovering the connection between psychological factors and the immune system. Their findings are based on an investigation of a massive drinking water contamination incident in Belgium in 2010, and are now published in the leading international medical journal Gut. [More]
Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events, which are expected to increase in frequency and intensity due to climate change, are associated with increased risk of Salmonella infections, according to a study led by researchers from the University of Maryland School of Public Health. [More]
Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Advertisement
Advertisement